Abstract
Purpose
The Caribbean population of Guadeloupe has one of the highest incidence rates of prostate cancer worldwide. In 2008, a population-based cancer registry was set up for the monitoring of cancer incidence in the aftermath of the environmental pollution with chlordecone, a persistent organochlorine insecticide formerly used in banana plantations. We describe the clinical presentation, incidence, mortality and survival of prostate cancer for the period 2008–2013.
Methods
The Guadeloupe cancer registry has been routinely collecting all incident cases of cancer since 2008. We compared age-specific incidence rates between different populations, and calculated incidence and mortality rates standardized to the world population. Kaplan–Meier observed survival and estimated age-standardized net survival were calculated by category for age, PSA level, and Gleason score using the Pohar-Perme method.
Results
Overall, 3,295 cases of prostate cancer were recorded. World-standardized incidence and mortality were respectively 184.1 [177.8–190.4] and 23.9 [21.9–25.7] per 100,000 person-years. At diagnosis, the mean age of patients was 68 ± 9.6 years old and 22% were aged over 75. Median PSA level was 8.9 [IQR: 6.0–16.0] and 13.6% of the patients had a Gleason ≥ 8. Five-year observed and net survivals were, respectively, 79.6% [77.9–81.2] and 90.7% [88.6–92.8].
Conclusion
The incidence of prostate cancer in Guadeloupe is among the highest in the world, along with those of the neighboring Caribbean countries and US African-Americans. We observed no decrease in incidence rates, and a decreasing but non-significant trend in mortality rates, which nonetheless remain higher than in high-income countries. Many Genome-Wide Association Studies are conducted to identify genetic markers involved in prostate cancer risk. In the Caribbean, complementary studies on both lifestyle and behavioral factors should highlight potential common risks among populations who share both genetic and environmental characteristics.
Similar content being viewed by others
References
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092. doi:10.1016/j.eururo.2012.02.054
Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane database of systematic reviews. BJU Int. doi:10.1002/14651858.CD004720
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990
Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H (2014) Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 12:26. doi:10.1186/1741-7015-12-26
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055. doi:10.1016/j.eururo.2013.12.062
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. Accessed 21 Jan 2017
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B (2004) Human prostate cancer risk factors. Cancer 101:2371–2490. doi:10.1002/cncr.20408
Hu WY, Shi GB, Hu DP, Nelles JL, Prins GS (2012) Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol 354(1–2):63–73. doi:10.1016/j.mce.2011.08.032
Bergman Å, Heindel JJ, Jobling S, Kidd K, Zoeller TR (2013) State of the science of endocrine disrupting chemicals 2012, 2013 edn. United Nations Environment Programme and the World Health Organization.
Mallick S, Blanchet P, Multigner L (2005) Prostate cancer incidence in guadeloupe, a French Caribbean archipelago. Eur Urol 47(6):769–772. doi:10.1016/j.eururo.2005.02.020
Cabidoche YM, Achard R, Cattan P, Clermont-Dauphin C, Massat F, Sansoulet J (2009) Long-term pollution by chlordecone of tropical volcanic soils in the French west indies: a simple leaching model accounts for current residue. Environ Pollut 157(5):1697–1705. doi:10.1016/j.envpol.2008.12.015
Crabit A, Cattan P, Colin F, Voltz M (2016) Soil and river contamination patterns of chlordecone in a tropical volcanic catchment in the French West Indies (Guadeloupe). Environ Pollut 212:615–626. doi:10.1016/j.envpol.2016.02.055
Dromard CR, Bodiguel X, Lemoine S, Bouchon-Navaro Y, Reynal L, Thouard E, Bouchon C (2016) Assessment of the contamination of marine fauna by chlordecone in Guadeloupe and Martinique (Lesser Antilles). Environ Sci Pollut Res 23(1):73–80. doi:10.1007/s11356-015-4732-z
Charlotte DR, Yolande BN, Cordonnier S, Claude B (2016) The invasive lionfish, Pterois volitans, used as a sentinel species to assess the organochlorine pollution by chlordecone in Guadeloupe (Lesser Antilles). Mar Pollut Bull. doi:10.1016/j.marpolbul.2016.04.012
Multigner L, Kadhel P, Rouget F, Blanchet P, Cordier S (2016) Chlordecone exposure and adverse effects in French West Indies populations. Environ Sci Pollut Res 23(1):3–8. doi:10.1007/s11356-015-4621-5
Grosclaude P, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M, Francim. R (2015) Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol 25(9):536–542. doi:10.1016/j.purol.2015.04.011
INSEE (2016) French population estimation from 1975 to 2015, by area, sex and age [Estimation de population au 1er janvier, par région, sexe et âge quinquennal]. http://www.insee.fr/fr/ppp/bases-de-donnees/donnees-detaillees/estim-pop/estim-pop-reg-sexe-aq-1975-2015.xls. Accessed May 2016
Doll R, Payne P (1966) Cancer incidence in five continents, vol 1. Union Internationale Contre le Cancer, Geneva
Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai
Cancer statistics SEER review 1975–2013. https://seer.cancer.gov/csr/1975-2013/results_merged/sec_23_prostate.pdf
Kim HJ, Fay P, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 19(3):335–351
Kaplan EL, Meier P (1958) Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 53(282):457–481. doi:10.1080/01621459.1958.10501452
Perme MP, Stare J, Esteve J (2012) On estimation in relative survival. Biometrics 68(1):113–120. doi:10.1111/j.1541-0420.2011.01640.x
Roche L, Danieli C, Belot A, Grosclaude P, Bouvier AM, Velten M, Iwaz J, Remontet L, Bossard N (2013) Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 132(10):2359–2369. doi:10.1002/ijc.27830
Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW (1996) Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335(5):304–310. doi:10.1056/NEJM199608013350502
Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ (1998) Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 160(5):1734–1738
Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64(1):10–19. doi:10.1111/j.1541-0420.2007.00825.x
Multigner L, Ndong JR, Giusti A, Romana M, Delacroix-Maillard H, Cordier S, Jegou B, Thome JP, Blanchet P (2010) Chlordecone exposure and risk of prostate cancer. J Clin Oncol 28(21):3457–3462. doi:10.1200/JCO.2009.27.2153
Emeville E, Broquere C, Brureau L, Ferdinand S, Blanchet P, Multigner L, Romana M (2014) Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS ONE 9(9):e107275. doi:10.1371/journal.pone.0107275
Lafontaine A, Hanikenne M, Boulangé-Lecomte C, Forget-Leray J, Thomé JP, Gismondi E (2016) Vitellogenin and vitellogenin receptor gene expression and 20-hydroxyecdysone concentration in Macrobrachium rosenbergii exposed to chlordecone. Environ Sci Pollut Res Int 23(20):20661–20671
Brureau L, Moningo D, Emeville E, Ferdinand S, Punga A, Lufuma S, Blanchet P, Romana M, Multigner L (2016) Polymorphisms of estrogen metabolism-related genes and prostate cancer risk in two populations of African Ancestry. PLoS ONE 11(4):e0153609. doi:10.1371/journal.pone.0153609
Kooiman GG, Martin FL, Williams JA, Grover PL, Phillips DH, Muir GH (2000) The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis 3(4):256–258. doi:10.1038/sj.pcan.4500489
Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, English DR, Giles GG (2012) Weight change and prostate cancer incidence and mortality. Int J Cancer 131(7):1711–1719. doi:10.1002/ijc.27414
Prevention CfDCa (2009) Differences in prevalence of obesity among black, white, and Hispanic adults—United States, 2006–2008. MMWR Morb Mortal Wkly Rep 58 (27):740–744
Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF, Bensen JT (2016) The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes Control 27(12):1475–1485. doi:10.1007/s10552-016-0828-0
Park SY, Haiman CA, Cheng I, Park SL, Wilkens LR, Kolonel LN, Le Marchand L, Henderson BE (2015) Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the multiethnic cohort study. Cancer Causes Control 26(10):1507–1515. doi:10.1007/s10552-015-0644-y
Daigre JL, Atallah A, Boissin JL, Jean-Baptiste G, Kangambega P, Chevalier H, Balkau B, Smadja D, Inamo J (2012) The prevalence of overweight and obesity, and distribution of waist circumference, in adults and children in the French Overseas Territories: the PODIUM survey. Diabetes Metab 38(5):404–411. doi:10.1016/j.diabet.2012.03.008
Gonzalez MC, Correia MITD, Heymsfield SB (2017) A requiem for BMI in the clinical setting. Curr Opin Clin Nutr Metab Care 20(5):314–321. doi:10.1097/MCO.0000000000000395
Von Hafe P, Pina F, Pérez A, Tavares M, Barros H (2004) Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 12(12):1930–1935. doi:10.1038/oby.2004.242
Razzaghi H, Quesnel-Crooks S, Sherman R, Joseph R, Kohler B, Andall-Brereton G, Ivey MA, Edwards BK, Mery L, Gawryszewski V, Saraiya M (2016) Leading causes of cancer mortality—Caribbean Region, 2003–2013. Morb Mortal Wkly Rep 65(49):1395–1400. doi:10.15585/mmwr.mm6549a3
Miller DC, Gelberg L, Kwan L, Stepanian S, Fink A, Andersen RM, Litwin MS (2008) Racial disparities in access to care for men in a public assistance program for prostate cancer. J Community Health 33(5):318–335. doi:10.1007/s10900-008-9105-9
Walsh PC (2005) Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. J Urol 174(4 Pt 1):1294–1295
Robbins AS, Yin D, Parikh-Patel A (2007) Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. Am J Epidemiol 166(1):71–78. doi:10.1093/aje/kwm052
Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L (2015) Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl 17(1):117–119. doi:10.4103/1008-682X.135127
Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH (2011) Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 71(10):1054–1063. doi:10.1002/pros.21320
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, Group CW (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010. doi:10.1016/S0140-6736(14)62038-9
Stroup AM, Cho H, Scoppa SM, Weir HK, Mariotto AB (2014) The impact of state-specific life tables on relative survival. J Natl Cancer Inst Monogr. doi:10.1093/jncimonographs/lgu017
Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–1598. doi:10.1093/jnci/djq366
Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ (2013) Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol 178(3):339–349. doi:10.1093/aje/kws580
Eeles R, Goh C, Castro E, Bancroft E, Guy M, Olama AAA, Easton D, Kote-Jarai Z (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11(1):18–31. doi:10.1038/nrurol.2013.266
Virlogeux V, Graff RE, Hoffmann TJ, Witte JS (2015) Replication and heritability of prostate cancer risk variants: Impact of population-specific factors. Cancer Epidemiol Biomarkers Prev 24(6):938–943. doi:10.1158/1055-9965.EPI-14-1372
Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(Suppl 1):S2. doi:10.1186/1750-9378-4-S1-S2
Funding
The cancer registry of Guadeloupe receives financial support from l’Institut National du Cancer (INCa) and Santé Publique France.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deloumeaux, J., Bhakkan, B., Eyraud, R. et al. Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry. Cancer Causes Control 28, 1265–1273 (2017). https://doi.org/10.1007/s10552-017-0962-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-017-0962-3